Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The researchers hypothesize that the addition of nesiritide to standard therapy will prevent
worsening of renal function in patients admitted to the hospital with decompensated heart
failure and renal dysfunction relative to standard therapy alone.